The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.f

Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

Publications

Eshuis M, Ahsmann EJ, van Egmond NH

[Fatal interstitial lung disease associated with erlotinib use].

Nederlands tijdschrift voor geneeskunde. 2013;157(7):A5519

Chou CL, Ko HW, Wang CW, Yu CT, Kuo HP, Huang CD

Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.

Chang Gung medical journal. 2010;33(1):100-5

Lind JS, Smit EF, Grünberg K, Senan S, Lagerwaard FJ

Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(9):1050-3

Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, Hoopes CW

Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2007;26(12):1340-4

Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG

Pulmonary toxicity associated with erlotinib.

Chest. 2007;132(3):1042-4

Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, Marquette CH

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

BMC cancer. 2007;7:150